...
首页> 外文期刊>Clinical Infectious Diseases >In Vitro Activity of Doripenem
【24h】

In Vitro Activity of Doripenem

机译:多利培南的体外活性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Doripenem is a carbapenem antibiotic that covers a wide range of gram-positive and gram-negative pathogens. In vitro studies have provided insight into certain features of doripenem's activity profile that may have particular relevance in the clinical setting. For instance, in vitro data indicate that doripenem combines the intrinsic activity of meropenem against gram-negative pathogens with the intrinsic activity of imipenem against gram-positive pathogens. Also notable is the fact that the in vitro activity of doripenem against problematic gram-negative pathogens, in particular Pseudomonas aeruginosa, is potent—recent data show that the minimum concentration necessary for inhibition of 90% of all isolates (MIC 90 ) of doripenem with respect to P. aeruginosa (4 µg/mL) is 2–4 times lower than the corresponding MIC 90 values of meropenem and imipenem. Furthermore, doripenem shows a limited ability to select for carbapenem-resistant mutants in vitro. Such experimental findings suggest that doripenem may represent a valuable option when carbapenem therapy is warranted for the treatment of serious infection.
机译:多利培南是一种碳青霉烯类抗生素,可覆盖多种革兰氏阳性和革兰氏阴性病原体。体外研究提供了多瑞培南活性谱某些特征的见解,这些特征可能与临床环境特别相关。例如,体外数据表明多利培南将美洛培南对革兰氏阴性病原体的固有活性与亚胺培南对革兰氏阳性病原体的固有活性结合起来。值得注意的是,多瑞培南对有问题的革兰氏阴性病原体,特别是铜绿假单胞菌的体外活性很强,最近的数据表明,抑制多瑞培南所有分离物(MIC 90)的90%所必需的最低浓度铜绿假单胞菌的含量(4 µg / mL)比美罗培南和亚胺培南的相应MIC 90值低2-4倍。此外,多瑞培南在体外选择抗碳青霉烯的突变体的能力有限。这样的实验结果表明,当需要使用碳青霉烯类药物治疗严重感染时,多利培南可能是一个有价值的选择。

著录项

  • 来源
    《Clinical Infectious Diseases》 |2009年第1期|p.11-16|共6页
  • 作者

    Daniel Sahm;

  • 作者单位

    Eurofins Medinet, Chantilly, Virginia;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号